Abstract
Purpose
Defining an optimal imaging modality for assessment of therapy and the best time of evaluation are pivotal for ideal patient’s management.
Methods
223Ra (Xofigo®, formerly Alpharadin) has been approved by the FDA and European Medicines Agency for treatment of metastatic castration-resistant prostate cancer with painful osseous involvement.
